Amolyt Pharma
Latest round
- Series C
Last raised
- Jan 2023
Total raised
- $228M
Investors
- 20
About Amolyt Pharma
Based in Ecully, France, and founded in 2015, Amolyt Pharma SAS, operates as a biotechnology company that develops and provides therapeutic peptides for patients with rare endocrine and metabolic diseases. Further, in March 2024, Amolyt Pharma SAS was acquired by AstraZeneca's Cardiovascular Medicine agreed to an upfront payment of USD 800 million, and will receive approximately USD 250 million upon achieving milestones through 2024. The clinical-stage global biotechnology company's pipeline focuses on two lead programs. Eneboparatide, a therapeutic peptide, is being developed for hypoparathyroidism, aiming to offer superior clinical benefits compared to existing treatments. AZP-3813, which targets acromegaly with its potent growth hormone receptor antagonist properties. Another program of the firm is AZP-40XX, which is a select group of monoclonal antibodies targeting the parathyroid receptor 1 for Primary Hyperparathyroidism (PHPT) and Humoral Hypercalcemia of Malignancy (HHM).
Who invested in Amolyt Pharma
20 investors across 3 rounds
See all investors in Amolyt Pharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Amolyt Pharma
Who invested in Amolyt Pharma?
Amolyt Pharma has 20 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Amolyt Pharma raised?
Amolyt Pharma has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Amolyt Pharma last raise money?
Amolyt Pharma's most recent round on record is a Series C, in Jan 2023.
What does Amolyt Pharma do?
Based in Ecully, France, and founded in 2015, Amolyt Pharma SAS, operates as a biotechnology company that develops and provides therapeutic peptides for patients with rare endocrine and metabolic diseases.
Where is Amolyt Pharma headquartered?
Amolyt Pharma is headquartered in France.
Which VCs invest in companies like Amolyt Pharma?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Amolyt Pharma's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Amolyt Pharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.